Cargando…

Comparative Adherence Trajectories of Oral Fingolimod and Injectable Disease Modifying Agents in Multiple Sclerosis

BACKGROUND: Oral fingolimod is convenient to use than injectable disease modifying agents (DMAs) in patients with multiple sclerosis (MS). However, the existing literature regarding the comparative adherence trajectories between oral fingolimod and injectable DMAs is limited. OBJECTIVE: To compare t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Earla, Jagadeswara R, Hutton, George J, Thornton, J Douglas, Chen, Hua, Johnson, Michael L, Aparasu, Rajender R
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7649232/ https://www.ncbi.nlm.nih.gov/pubmed/33177813 http://dx.doi.org/10.2147/PPA.S270557

Ejemplares similares

Factors associated with oral fingolimod use over injectable disease- modifying agent use in multiple sclerosis
por: Earla, Jagadeswara Rao, et al.
Publicado: (2021)

Marginal Health Care Expenditure Burden Among U.S. Civilian Noninstitutionalized Individuals with Multiple Sclerosis: 2010-2015
por: Earla, Jagadeswara Rao, et al.
Publicado: (2020)

Antimuscarinic Discontinuation in Patients with Overactive Bladder in Nursing Homes: A Retrospective Study of Medicare Beneficiaries
por: Aparasu, Rajender R., et al.
Publicado: (2020)

Assessing treatment switch among patients with multiple sclerosis: A machine learning approach
por: Li, Jieni, et al.
Publicado: (2023)

Determination of Seminal Concentration of Fingolimod and Fingolimod‐Phosphate in Multiple Sclerosis Patients Receiving Chronic Treatment With Fingolimod
por: David, Olivier J., et al.
Publicado: (2017)

Efficacy of fingolimod is superior to injectable disease modifying therapies in second-line therapy of relapsing remitting multiple sclerosis
por: Braune, Stefan, et al.
Publicado: (2015)

Phase IV study of retention on fingolimod versus injectable multiple sclerosis therapies: a randomized clinical trial
por: Cree, Bruce A.C., et al.
Publicado: (2018)

Adherence to fingolimod in multiple sclerosis: an investigator-initiated, prospective, observational, single-center cohort study
por: Zimmer, Andrea, et al.
Publicado: (2017)

Factors influencing prescribing the first add-on disease-modifying antirheumatic drugs in patients initiating methotrexate for rheumatoid arthritis
por: Huang, Yinan, et al.
Publicado: (2023)

Paraquat - A deadly poison: Report of a case and review
por: Saravu, Kavitha, et al.
Publicado: (2013)

Multiple Sclerosis Relapses Following Cessation of Fingolimod
por: Malpas, Charles B., et al.
Publicado: (2022)

Development of oral agent in the treatment of multiple sclerosis: how the first available oral therapy, fingolimod will change therapeutic paradigm approach
por: Gasperini, Claudio, et al.
Publicado: (2012)

Fingolimod (FTY720): First approved oral therapy for multiple sclerosis
por: Sharma, Sushil, et al.
Publicado: (2011)

Modulation of Cardiac Autonomic Function by Fingolimod Initiation and Predictors for Fingolimod Induced Bradycardia in Patients with Multiple Sclerosis
por: Li, Kai, et al.
Publicado: (2017)

Safety and Efficacy of Fingolimod in Treatment-Naïve Multiple Sclerosis Patients
por: Marriott, James J.
Publicado: (2011)

Natalizumab versus fingolimod and dimethyl fumarate in multiple sclerosis treatment
por: Vollmer, Brandi L., et al.
Publicado: (2018)

Outpatient opioid prescribing by Alzheimer’s diagnosis among older adults with pain in United States
por: Huang, Yinan, et al.
Publicado: (2023)

Critical appraisal of the role of fingolimod in the treatment of multiple sclerosis
por: Warnke, Clemens, et al.
Publicado: (2011)

Myeloid cells as target of fingolimod action in multiple sclerosis
por: Di Dario, Marco, et al.
Publicado: (2015)

An observational study of alemtuzumab following fingolimod for multiple sclerosis
por: Willis, Mark, et al.
Publicado: (2017)

Risk factors for fingolimod-induced lymphopenia in multiple sclerosis
por: Ohtani, Ryohei, et al.
Publicado: (2018)

Fingolimod-Associated Macular Edema in the Treatment of Multiple Sclerosis
por: Khan, Asma A, et al.
Publicado: (2023)

A concise synthesis of Fingolimod: an orally available drug for treating multiple sclerosis
por: Yan, Ning, et al.
Publicado: (2015)

Disseminated Histoplasmosis in a Patient With Multiple Sclerosis Treated With Fingolimod
por: Abrahamowicz, Aleksandra A., et al.
Publicado: (2021)

Compliance to fingolimod and other disease modifying treatments in multiple sclerosis patients, a retrospective cohort study
por: Agashivala, Neetu, et al.
Publicado: (2013)

Antipsychotic Use and Risk of Nursing Home Admission Among Dual-Eligible Medicare Beneficiaries: A Propensity-Matched Study
por: Aparasu, Rajender R., et al.
Publicado: (2015)

Pain management practices for outpatients with breast cancer
por: Talwar, Ashna, et al.
Publicado: (2022)

Cost comparison of adverse event management among breast and ovarian cancer patients treated with poly (ADP-ribose) polymerase inhibitors: analysis based on phase 3 clinical trials
por: Fan, Lin, et al.
Publicado: (2022)

Rituximab versus natalizumab, fingolimod, and dimethyl fumarate in multiple sclerosis treatment
por: Vollmer, Brandi L., et al.
Publicado: (2020)

Synthesis and Biological Evaluation of Fingolimod Derivatives as Antibacterial Agents
por: Zore, Matej, et al.
Publicado: (2021)

Fingolimod (Gileyna, FTY720): Innovative treatment for multiple sclerosis
por: Pinki,, et al.
Publicado: (2011)

Effect of Fingolimod on Platelet Count Among Multiple Sclerosis Patients
por: Farrokhi, Mehrdad, et al.
Publicado: (2015)

Effect of Fingolimod on Brain Volume Loss in Patients with Multiple Sclerosis
por: De Stefano, Nicola, et al.
Publicado: (2017)

Fingolimod as a Treatment in Neurologic Disorders Beyond Multiple Sclerosis
por: Bascuñana, Pablo, et al.
Publicado: (2020)

Modulation of Tregs and iNKT by Fingolimod in Multiple Sclerosis Patients
por: Ferraro, Diana, et al.
Publicado: (2021)

Fingolimod‐induced bladder lymphoma in a patient with multiple sclerosis
por: Vaheb, Saeed, et al.
Publicado: (2023)

Metabolomic Changes in Patients Affected by Multiple Sclerosis and Treated with Fingolimod
por: Murgia, Federica, et al.
Publicado: (2023)

Neurological update: treatment escalation in multiple sclerosis patients refractory to fingolimod—potentials and risks of subsequent highly active agents
por: Korsen, Melanie, et al.
Publicado: (2022)

An evaluation of adherence in patients with multiple sclerosis newly initiating treatment with a self-injectable or an oral disease-modifying drug
por: Munsell, Michael, et al.
Publicado: (2016)

Prevalence and Factors Associated with Cumulative Anticholinergic Burden Among Older Long-Stay Nursing Home Residents with Overactive Bladder
por: Chatterjee, Satabdi, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_lo5s1l7v88dchtq5jb94v9lo4v